N
SGMO

Natixis’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Natixis’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-181,019
Closed -$749K – 1168
2022
Q2 		$749K Buy
+181,019
New +$783K ﹤0.01% 878
2022
Q1 		– Sell
-15,598
Closed -$117K – 1317
2021
Q4 		$117K Sell
15,598
-8,485
-35% -$73.7K ﹤0.01% 1187
2021
Q3 		$217K Buy
+24,083
New +$238K ﹤0.01% 1140

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Natixis's SGMO Position: Q3 2022 in Review

Natixis sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2022, closing a stake of 181,019 shares — an estimated $749K sold.

Natixis first reported a position in SGMO in Q3 2021 and held it in 3 quarters. The position peaked at $749K in Q2 2022. 197 funds tracked by Wall St. Rank hold SGMO as of Q3 2022.

  • Natixis reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2022 after selling out during the quarter.
  • Natixis sold 181,019 SANGAMO THERAPEUTICS INC shares in Q3 2022, an estimated $749K.
  • Natixis first reported a position in SANGAMO THERAPEUTICS INC in Q3 2021 and held it in 3 quarters.
  • Natixis's SANGAMO THERAPEUTICS INC position peaked at $749K in Q2 2022.
  • 197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2022.

Based on Natixis's 13F filing for Q3 2022, filed 14 Nov 2022.